Dandelion Root Extract in Patients with Refractory Hematologic Malignancies
Thirty patients with refractory (end stage) blood related cancers (lymphoma, leukemia, myelodysplastic syndromes) will be entered into the protocol in groups of three. Each subsequent group of three will have an increase in the dose of DRE until unacceptable side effects are experience by at least two out of the three in that group. Unacceptable side effects include admission to hospital for side effects related to the drug, death or inability to consume the recommended dose. Once dose limiting toxicity is identified, we move back to dose level previous to the one that causes the serious event, and that will be the recommended dose.
The design of this dose-finding phase I clinical trial was chosen to assess the DRE in the treatment of patients with refractory hematologic malignancies. Patients will be eligible for this study if they have a refractory hematologic malignancy and have exhausted all standard medical treatments for their cancer. Patients must not be pregnancy and must be at least 18 years of age and not over 70 years of age. Patients cannot have significant comorbidites that would increase the risk of death or toxicity from this product. They must be capable of adhering to the protocol.
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society